Norges Bank’s Tourmaline Bio TRML Stock Holding History

Norges Bank’s Portfolio TRML Stock Details TRML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-27,261	Closed	-$4.17M	–	2236
2021 Q4	$4.17M	Buy	+27,261	New	+$4.03M	﹤0.01%	1932

Other funds holding TRML

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

QUSVM

Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Norges Bank's TRML Position: Q1 2022 in Review

Norges Bank sold out of Tourmaline Bio (TRML) in Q1 2022, closing a stake of 27,261 shares — an estimated $4.17M sold.

Norges Bank first reported a position in TRML in Q4 2021 and held it in 1 quarter. The position peaked at $4.17M in Q4 2021. 51 funds tracked by Wall St. Rank hold TRML as of Q1 2022.

Norges Bank reported no remaining Tourmaline Bio position as of Q1 2022 after selling out during the quarter.
Norges Bank sold 27,261 Tourmaline Bio shares in Q1 2022, an estimated $4.17M.
Norges Bank first reported a position in Tourmaline Bio in Q4 2021 and held it in 1 quarter.
Norges Bank's Tourmaline Bio position peaked at $4.17M in Q4 2021.
51 funds tracked by Wall St. Rank held Tourmaline Bio as of Q1 2022.

Based on Norges Bank's 13F filing for Q1 2022, filed 9 May 2022.